7Baggers
 Lipella Pharmaceuticals Announces Positive Phase 2a Results  TipRanks Thu, 18 Sep 2025 07:00:00 GMT
 published on: 2025-09-11 19:19:14  Newser Fri, 12 Sep 2025 00:19:14 GMT
 published on: 2025-09-10 02:31:59  Newser Wed, 10 Sep 2025 07:31:59 GMT
 published on: 2025-09-08 07:56:28  Newser Mon, 08 Sep 2025 12:56:28 GMT
 published on: 2025-09-03 04:19:32  Newser Wed, 03 Sep 2025 09:19:32 GMT
 published on: 2025-09-01 21:34:54  Newser Tue, 02 Sep 2025 02:34:54 GMT
 published on: 2025-08-31 09:37:01  Newser Sun, 31 Aug 2025 14:37:01 GMT
 published on: 2025-08-31 08:26:24  Newser Sun, 31 Aug 2025 13:26:24 GMT

Lipella Pharmaceuticals Inc.
(NASDAQ:LIPO) 

LIPO stock logo

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinic...

Founded: 2005
IPO Price: $5.75 (Dec 20, 2022)
Full Time Employees: 4
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends